Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of Cytisinicline in Healthy Smokers
NCT05566288Phase 1Completed
- Sponsor
- Achieve Life Sciences
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cytisinicline in nicotine dependence (8 arms), sponsored by Achieve Life Sciences. Primary endpoint: Predicted Placebo-Adjusted Change From Baseline in the Corrected QT Interval using Fridericia's Formula. Started Oct 2022; status: completed.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT05566288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566288.